eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
5.11
-0.06 (-1.26%)
Aug 7, 2026, 4:00 PM EDT - Market closed
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
46.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 151.12M |
| Metagenomi Therapeutics | 22.33M |
| Immutep | 5.28M |
| Seres Therapeutics | 1.88M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 35.00K |
EXOZ News
- 17 days ago - eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing - Accesswire
- 25 days ago - eXoZymes Inc trading resumes - TheFly
- 25 days ago - eXoZymes Inc trading halted, volatility trading pause - TheFly
- 6 weeks ago - eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery - Accesswire
- 7 weeks ago - eXoZymes Inc. Announces Closing of $6 Million Public Offering - Accesswire
- 2 months ago - eXoZymes prices 592,270 shares at $18.00 in public offering - TheFly
- 2 months ago - eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants - Accesswire
- 3 months ago - eXoZymes Quarterly report: Q1 2026 - Filings